ClinicalTrials.gg
CompletedNCT05573100Updated May 3, 2024

The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)

A Phase 2 interventional study of CU06-1004 in Diabetic Macular Edema, sponsored by Curacle Co., Ltd.. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by Curacle Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.

Enrollment
101st of 244
67 · median 45
Started
2022
with 9 others
Phase 2
63 of 276
3 open now
Registered
230th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 101st largest by enrollment of the 244 interventional ones that give a count, is one of 10 that started in 2022, is one of 63 in phase 2, and was the 230th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 12 weeks. The study will have a 1:1:1 randomization (CU06-1004 100mg: CU06-1004 200mg: CU06-1004 300mg).

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
  • Endothelial dysfunction blocker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject who is male or female ≥ 18 years of age
  2. Subject who has a diagnosis of Type 1 or 2 diabetes mellitus
  3. Subject who has study eye with definite retinal thickening due to diabetic macular edema involving the center of the macula
  4. Subject who has voluntarily signed an form
  5. Subject who has study eye with central subfield thickness (CST) of the following on SD-optical coherence tomography (OCT).

    1. Zeiss Cirrus: CST ≥ 290 µm in women, or ≥ 305 µm in men
    2. Heidelberg Spectralis: CST ≥ 305 µm in women, or ≥ 320 µm in men
  6. Subject who has DRSS score ≥ 35
  7. Subject who has study eye with an ETDRS BCVA letter score ranging from 34 to 83, inclusive (approximate Snellen equivalent of 20/25 - 20/200 at a distance of 4 meters).
  8. Subject who has media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs.

Exclusion criteria

Exclusion Criteria:

  1. Subject whose macular edema is of non-diabetic retinopathy etiology (e.g., secondary to vitreomacular interface abnormalities).
  2. Subject who has had major surgery within 3 months prior to randomization or major surgery planned during the next 6 months.
  3. Subject who has a to any of the product or similar class of drug and ingredient.
  4. Subject who has the following illness or abnormal laboratory test values:

    • Uncontrolled hypertension (SBP > 180 mmHg or DBP > 100 mmHg)
    • Uncontrolled diabetes ( > 12.0%)
    • Total > 1.5 ×
    • Positive results for or or C viruses
    • Other abnormal lab values per Investigator's judgement
  5. Subject who participated in an investigational trial of biologic agent within 3 months and any other investigational trial within 1 month of randomization.
  6. Subject who has received gene therapy for any indication.
  7. Subject who has received COVID-19 vaccine within 30 days of first dosing until the end of the study.
  8. Pregnant woman, lactating woman, or female or male subject of who doesn't accept appropriate measures for the next 6 months

    * Hormonal contraceptives, intrauterine contraceptive device, sterilization of spouse (e.g., vasectomy, tubal ligation), double-barrier method (e.g., combinational use of spermicides and condoms, diaphragm, contraceptive sponge, or FemCap)

  9. Subject who has medical condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
  10. Subject who administered vaccinium myrtillus extract or dobesilate calcium within 2 weeks before randomization.
  11. Subject who has unstable angina, myocardial infarction, , cerebral infarction, coronary artery bypass surgery, or transluminal coronary angioplasty within 6 months before screening.
  12. Subject who has an ocular condition (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, foveal atrophy, pigmentary changes, dense subfoveal hard exudates, nonretinal condition etc.).
  13. Subject who has exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.
  14. Subject who is expected to have no improvement of decreased visual acuity in the opinion of the Investigator, even if macular edema is resolved (e.g., foveal atrophy, abnormal pigmentation, dense subfoveal hard exudate).
  15. Subject who has a history of treatment with anti-VEGF agents, or focal laser treatment (Focal/grid laser photocoagulation) within 3 months prior to randomization or intravitreal dexamethasone or triamcinolone within 6 months prior to randomization.
  16. Subject who has a history of treatment with intravitreal fluocinolone astonide.
  17. Subject who has a history of panretinal scatter photocoagulation (PRP).
  18. Subject who anticipated need for PRP in the 3 months following randomization.
  19. Subject who has a history of ocular surgery (including cataract extraction, any intraocular surgery, etc.) within prior 3 months or anticipated within the next 6 months following randomization.
  20. Subject who has a history of retinal detachment or retinal detachment repair surgery.
  21. Subject who has a history of YAG capsulotomy performed within 2 months prior to randomization.
  22. Subject who has uncontrolled glaucoma in either eye (intraocular pressure (IOP) > 24 mmHg on medication or according to the investigator's judgment).
  23. Subject who has a history of vitrectomy.
  24. Subject who has any active intraocular inflammatory diseases such as uveitis, conjunctivitis, and in either eye.
  25. Subject who has any history of intraocular inflammation in either eye other than what would be expected in the normal post-operative course following prior routine ocular surgery such as cataract surgery.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    CU06-1004 100mg

    CU06-1004 100 mg tablets. Dosed at 100 mg (1 capsule) QD within 30 minutes after meal on each evening

    Drug: CU06-1004

  • Experimental
    CU06-1004 200mg

    CU06-1004 100 mg tablets. Dosed at 200 mg (2 capsules) QD within 30 minutes after meal on each evening

    Drug: CU06-1004

  • Experimental
    CU06-1004 300mg

    CU06-1004 100 mg tablets. Dosed at 300 mg (3 capsules) QD within 30 minutes after meal on each evening

    Drug: CU06-1004

Interventions

  • CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.

    Also known as: SAC-1004, CU06, CU06-RE

06

What researchers measure

Primary outcomes

  1. The change of central subfield thickness (CST)

    Change in CST in the study eye assessed by SD-OCT at Week 12 compared to baseline

    Time frame: Baseline and 12 weeks

  2. To determine the optimal doses

    The 1:1:1 randomization is fitting for the study objective to determine the optimal doses for a phase 2b study.

    Time frame: 12 weeks

Secondary outcomes

  1. The change of central subfield thickness (CST)

    Change in CST in the study eye assessed by SD-OCT Weeks 4 and 8 compared to baseline

    Time frame: Baseline, 4 weeks and 8 weeks

  2. The change of all other subfield thickness

    Change in all other subfield thickness (Nasal, temporal, superior and inferior) in the study eye assessed by SD-OCT at Weeks 4, 8, and 12 compared to baseline

    Time frame: Baseline, 4 weeks, 8 weeks and 12 weeks

  3. The change of early treatment diabetic retinopathy study (ETDRS) best-corrected visual acuity (BCVA) letter score

    Change in ETDRS BCVA letter score in the study eye at Weeks 4, 8, and 12 compared to baseline

    Time frame: Baseline, 4 weeks, 8 weeks and 12 weeks

  4. Change in diabetic retinopathy severity scale (DRSS)

    Change in DRSS in the study eye at Weeks 12 compared to baseline

    Time frame: Baseline and 12 weeks

  5. The change of blood biomarkers

    Change in blood biomarker (TNF-alpha, IL-1 beta, IL-6) at Week 12 compared to baseline

    Time frame: Baseline and 12 weeks

  6. Number and severity of treatment emergent adverse events (TEAEs)

    Number and severity of TEAEs up to Week 12 compared to baseline

    Time frame: Baseline and 12 weeks

07

Study locations

11 sites
  • Rand Eye Institute
    Deerfield Beach, Florida 33064, United States
  • Elman Retina Group
    Baltimore, Maryland 21237, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • New England Retina Consultants
    Springfield, Massachusetts 01107, United States
  • Mid Atlantic Retina
    Bethlehem, Pennsylvania 18017, United States
  • Austin Research Center for Retina
    Austin, Texas 78705, United States
  • Retina consultant of Texas
    Bellaire, Texas 77339, United States
  • Valley Retina Institute
    McAllen, Texas 78503, United States
  • Wagner Macula and Retina Center
    Norfolk, Virginia 23454, United States
  • Emanuelli Research & Development Center
    Arecibo, 00612, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in May 2023, 5 months.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 5 months is below that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2022
First posted
Oct 10, 2022
StartActual
Dec 21, 2022
Primary completionActual
May 31, 2023
CompletionActual
Jun 30, 2023
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05573100
Lead sponsor
Curacle Co., Ltd.
Collaborators
Théa Open Innovation, France
Responsible party
Sponsor
First posted
Oct 10, 2022
Start date
Dec 21, 2022
Primary completion
May 31, 2023
Completion
Jun 30, 2023
Last update
May 3, 2024

Study contacts

Pankyung Kim, M.S
study director · Curacle Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CU06-1004

Start the discussion